176 related articles for article (PubMed ID: 27330726)
21. Cost-effectiveness analysis of metformin+dipeptidyl peptidase-4 inhibitors compared to metformin+sulfonylureas for treatment of type 2 diabetes.
Kwon CS; Seoane-Vazquez E; Rodriguez-Monguio R
BMC Health Serv Res; 2018 Feb; 18(1):78. PubMed ID: 29391064
[TBL] [Abstract][Full Text] [Related]
22. Early glycaemic control in metformin users receiving their first add-on therapy: a population-based study of 4,734 people with type 2 diabetes.
Thomsen RW; Baggesen LM; Søgaard M; Pedersen L; Nørrelund H; Buhl ES; Haase CL; Johnsen SP
Diabetologia; 2015 Oct; 58(10):2247-53. PubMed ID: 26277380
[TBL] [Abstract][Full Text] [Related]
23. Alogliptin in Patients with Type 2 Diabetes Receiving Metformin and Sulfonylurea Therapies in the EXAMINE Trial.
White WB; Heller SR; Cannon CP; Howitt H; Khunti K; Bergenstal RM;
Am J Med; 2018 Jul; 131(7):813-819.e5. PubMed ID: 29581078
[TBL] [Abstract][Full Text] [Related]
24. Determinants of Glycemic Response to Add-On Therapy with a Dipeptidyl Peptidase-4 Inhibitor: A Retrospective Cohort Study Using a United Kingdom Primary Care Database.
Mamza J; Mehta R; Donnelly R; Idris I
Diabetes Technol Ther; 2016 Feb; 18(2):85-92. PubMed ID: 26752504
[TBL] [Abstract][Full Text] [Related]
25. Comparative cardiovascular safety of glucagon-like peptide-1 receptor agonists versus other antidiabetic drugs in routine care: a cohort study.
Patorno E; Everett BM; Goldfine AB; Glynn RJ; Liu J; Gopalakrishnan C; Kim SC
Diabetes Obes Metab; 2016 Aug; 18(8):755-65. PubMed ID: 27003762
[TBL] [Abstract][Full Text] [Related]
26. Change in glycated haemoglobin levels after initiating second-line therapy in type 2 diabetes: a primary care database study.
Rathmann W; Bongaerts B; Kostev K
Diabetes Obes Metab; 2016 Aug; 18(8):840-3. PubMed ID: 27062643
[TBL] [Abstract][Full Text] [Related]
27. Meta-analysis of factors associated with antidiabetic drug prescribing for type 2 diabetes mellitus.
Mahmoud F; Mullen A; Sainsbury C; Rushworth GF; Yasin H; Abutheraa N; Mueller T; Kurdi A
Eur J Clin Invest; 2023 Aug; 53(8):e13997. PubMed ID: 37002856
[TBL] [Abstract][Full Text] [Related]
28. Comparison of baseline characteristics and clinical course in Japanese patients with type 2 diabetes among whom different types of oral hypoglycemic agents were chosen by diabetes specialists as initial monotherapy (JDDM 42).
Fujihara K; Igarashi R; Matsunaga S; Matsubayashi Y; Yamada T; Yokoyama H; Tanaka S; Shimano H; Maegawa H; Yamazaki K; Kawai K; Sone H
Medicine (Baltimore); 2017 Feb; 96(7):e6122. PubMed ID: 28207538
[TBL] [Abstract][Full Text] [Related]
29. A randomized controlled trial of the efficacy and safety of saxagliptin as add-on therapy in patients with type 2 diabetes and inadequate glycaemic control on metformin plus a sulphonylurea.
Moses RG; Kalra S; Brook D; Sockler J; Monyak J; Visvanathan J; Montanaro M; Fisher SA
Diabetes Obes Metab; 2014 May; 16(5):443-50. PubMed ID: 24205943
[TBL] [Abstract][Full Text] [Related]
30. [A combination of dipeptidyl peptidase-4 inhibitor and metformin in the treatment of patients with type 2 diabetes mellitus: effective control of glycemia, weight, and quantitative body composition].
Shestakova MV; Suhareva OIu; Chernova TO; Shmushkovich IA; Aleksandrov AA; Il'in AV; Dedov II
Ter Arkh; 2013; 85(8):49-55. PubMed ID: 24137964
[TBL] [Abstract][Full Text] [Related]
31. Factors Associated with Type 2 Diabetes Mellitus Treatment Choice Across Four European Countries.
Heintjes EM; Overbeek JA; Hall GC; Prieto-Alhambra D; Lapi F; Hammar N; Bezemer ID
Clin Ther; 2017 Nov; 39(11):2296-2310.e14. PubMed ID: 29108837
[TBL] [Abstract][Full Text] [Related]
32. Choosing Dipeptidyl Peptidase-4 Inhibitors, Sodium-glucose Cotransporter-2 Inhibitors, or Both, as Add-ons to Metformin: Patient Baseline Characteristics Are Crucial.
Goldenberg RM
Clin Ther; 2017 Dec; 39(12):2438-2447. PubMed ID: 29174215
[TBL] [Abstract][Full Text] [Related]
33. Diabetes treatment intensification and associated changes in HbA1c and body mass index: a cohort study.
Roumie CL; Greevy RA; Grijalva CG; Hung AM; Liu X; Griffin MR
BMC Endocr Disord; 2016 Jun; 16(1):32. PubMed ID: 27255309
[TBL] [Abstract][Full Text] [Related]
34. Dapagliflozin compared with other oral anti-diabetes treatments when added to metformin monotherapy: a systematic review and network meta-analysis.
Goring S; Hawkins N; Wygant G; Roudaut M; Townsend R; Wood I; Barnett AH
Diabetes Obes Metab; 2014 May; 16(5):433-42. PubMed ID: 24237939
[TBL] [Abstract][Full Text] [Related]
35. Dipeptidyl peptidase-4 inhibitors for treatment of type 2 diabetes mellitus in the clinical setting: systematic review and meta-analysis.
Karagiannis T; Paschos P; Paletas K; Matthews DR; Tsapas A
BMJ; 2012 Mar; 344():e1369. PubMed ID: 22411919
[TBL] [Abstract][Full Text] [Related]
36. Comparison of antidiabetic drugs added to sulfonylurea monotherapy in patients with type 2 diabetes mellitus: A network meta-analysis.
Qian D; Zhang T; Tan X; Zheng P; Liang Z; Xie J; Jiang J; Situ B
PLoS One; 2018; 13(8):e0202563. PubMed ID: 30148851
[TBL] [Abstract][Full Text] [Related]
37. The efficacy and safety of DPP4 inhibitors compared to sulfonylureas as add-on therapy to metformin in patients with Type 2 diabetes: A systematic review and meta-analysis.
Mishriky BM; Cummings DM; Tanenberg RJ
Diabetes Res Clin Pract; 2015 Aug; 109(2):378-88. PubMed ID: 26059071
[TBL] [Abstract][Full Text] [Related]
38. Safety and efficacy of vildagliptin: 52-week post-marketing surveillance of Japanese patients with type 2 diabetes in combination with other oral antidiabetics and insulin.
Hayashi T; Murayama H; Shinfuku Y; Taniguchi T; Tsumiyama I; Oyama N
Expert Opin Pharmacother; 2020 Jan; 21(1):121-130. PubMed ID: 31689132
[No Abstract] [Full Text] [Related]
39. Hypoglycemia Incidence Rates and Associated Health Care Costs in Patients with Type 2 Diabetes Mellitus Treated with Second-Line Linagliptin or Sulfonylurea After Metformin Monotherapy.
Raju A; Shetty S; Cai B; D'Souza AO
J Manag Care Spec Pharm; 2016 May; 22(5):483-92. PubMed ID: 27123911
[TBL] [Abstract][Full Text] [Related]
40. Comparison of costs and outcomes of dapagliflozin with other glucose-lowering therapy classes added to metformin using a short-term cost-effectiveness model in the US setting.
Chakravarty A; Rastogi M; Dhankhar P; Bell KF
J Med Econ; 2018 May; 21(5):497-509. PubMed ID: 29376760
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
